Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Drug design platinum anticancer drugs

Hambley and co-workers have reported the synthesis, DNA cross-linking, and in vitro anticancer properties of a platinum(II) complex that was designed to bind the macromolecule in an interstrand rather than intrastrand manner,162 the latter being the dominant mode of DNA-binding by platinum anticancer drugs such as cisplatin. The complex [PtCl2(hpip)] ((46) ... [Pg.694]

The recent clinical success of platinum anticancer drugs has illustrated that metal complexes can be designed to have a specificity of biological activity. For example, not all platinum complexes are active anticancer agents. Some platinum complexes are inert and relatively non-toxic, some attack DNA, some do not. In general, the nature of the metal ion itself, its oxidation state, and the types and number of bound ligands can all play critical roles in the biological activity [4, 5]. [Pg.39]

Feazell, R.P. et al. (2007) Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. Journal of the American Chemical Society, 129 (27), 8438-8439. [Pg.215]

CONTROLLING PLATINUM, RUTHENIUM, AND OSMIUM REACTIVITY FOR ANTICANCER DRUG DESIGN... [Pg.1]

In our group, a major part of our research is devoted to the design of new anticancer drugs. Our recent efforts towards the discovery of new platinum-, ruthenium- and osmium-based anticancer agents provide the topic for this account and a section is devoted to each metal. We focus on recent results from our lab in the context of other developments and related research in this field (hence our coverage of the field is focused on these areas and is not comprehensive). [Pg.2]

Controlling Platinum, Ruthenium,and Osmium Reactivity for Anticancer Drug Design... [Pg.521]

Fig.1 Selected platinum-based anticancer compoimds a cisplatin second generation anticancer drugs b carboplatin, c nedaplatin and d oxaliplatin and novel complexes with interesting dinical properties such as the orally administered e satraplatin and complexes designed to overcome cisplatin resistance f trans-dipyridine dichloroplatinum and g a platinum amino phosphine complex... Fig.1 Selected platinum-based anticancer compoimds a cisplatin second generation anticancer drugs b carboplatin, c nedaplatin and d oxaliplatin and novel complexes with interesting dinical properties such as the orally administered e satraplatin and complexes designed to overcome cisplatin resistance f trans-dipyridine dichloroplatinum and g a platinum amino phosphine complex...

See other pages where Drug design platinum anticancer drugs is mentioned: [Pg.11]    [Pg.20]    [Pg.282]    [Pg.187]    [Pg.2]    [Pg.16]    [Pg.57]    [Pg.667]    [Pg.334]    [Pg.577]    [Pg.107]    [Pg.209]    [Pg.605]    [Pg.266]    [Pg.321]    [Pg.445]    [Pg.292]    [Pg.187]    [Pg.58]    [Pg.179]    [Pg.179]   
See also in sourсe #XX -- [ Pg.8 , Pg.9 , Pg.10 ]




SEARCH



Anticancer drugs

Anticancer drugs platinum

Platinum anticancer

© 2024 chempedia.info